

## AAPS News Releases and Media Advisories

FOR IMMEDIATE RELEASE  
November 8, 2009

**Contact:**  
Joseph Catapano  
Communications Specialist - AAPS  
Tel: 1-703-248-4740  
E-mail: [Joseph Catapano](mailto:Joseph.Catapano@AAPS.org)

## AAPS Announces 2009 Fellows

21 Honored For Outstanding Contributions to the Pharmaceutical Sciences

**EMBARGO:**  
**November 8, 2009 at 4 p.m.**

### On-Site Contact:

Joe Catapano  
AAPS  
213-743-6208  
[CatapanoJ@aaps.org](mailto:CatapanoJ@aaps.org)

**LOS ANGELES, CA** (November 8, 2009) – The American Association of Pharmaceutical Scientists (AAPS) is pleased to announce its 2009 AAPS Fellows. An individual is granted the honor of being named AAPS Fellow after making sustained remarkable scholarly and research contributions to the pharmaceutical sciences such as original articles, scientific presentations at AAPS Annual Meetings, and/or patents.

**Lawrence H. Block, Ph.D.** is Professor of Pharmaceutics at Duquesne University. His research interests lie in the transport properties of solutions of the macromolecular and polymeric materials employed as excipients in pharmaceutical and cosmetic formulations. Seventy-eight presentations at regional, national, and international scientific meetings, 24 publications, two patents, and 24 of his graduate students' theses and dissertations have been based on research in his lab on various excipients as part of his effort to characterize these materials, their functionality, and potential applicability to pharmaceutical formulations.

**Ubaldo Conte, Pharm.D.** is Full Professor at the University of Pavia (Italy). His research interests regarding the development of solid dosage forms (Geomatrix) and drug release systems, made him renowned among the pharmaceutical sciences community. Other interests focus on the physics of powder compression, powder and tablet technology, disintegration mechanisms of solid dosage forms, suspension technology, and solid phase drug interactions. His scientific production is provided through roughly 200 publications and 57 patents.

**Robert W. Curley, Jr., Ph.D.** is Professor of Medicinal Chemistry at The Ohio State University, College of Pharmacy. He has spent nearly 30 years researching the chemistry and biochemistry of vitamin A derivatives (retinoids). His specific interests include developing stable analogs of unstable metabolites of retinoids in order to improve their breast cancer chemopreventive and therapeutic activity and reduce their toxicity.

**David Z. D'Argenio, Ph.D.** is Professor of Biomedical Engineering at the University of Southern California and holder of the Chonette Chair of Biomedical Technology. His research has included the development of modeling methodologies for pharmacokinetic/pharmacodynamic systems analysis including the development of the ADAPT software that is designed to facilitate the discovery, exploration, and application of the underlying pharmacokinetic and pharmacodynamic properties of drugs.

**Ping Gao, Ph.D.** is Director of Global Pharmaceutical and Analytical Sciences at Abbott Laboratories, and has made

significant technical contributions to four marketed New Chemical Entity drug products. He has 36 patents and patent applications, and has made significant contributions in the areas of characterization of drug release kinetics and mechanism, developing and applying novel in vitro biorelevant drug release tests, developing proprietary lipid-based drug delivery systems, and applying enabling drug delivery technologies for drug product development. He has published 47 scientific manuscripts in peer-reviewed journals and book chapters and delivered over 70 presentations on pharmaceutical technology related topics.

**Stephen W. Hoag, Ph.D.** is Assistant Professor at the University of Maryland. He has published on the thermodynamics of tablet compaction, principles of powder behavior, excipient functionality, drug stability, and folic acid dissolution from prenatal vitamins. His research has increased understanding of pharmaceutical systems, which will give a clearer insight into how to make better delivery systems and provide a rational basis for formulation development, manufacturing and regulatory policy.

**Ken-ichi Hosoya, Ph.D.** is Professor and Chair of the Department of Pharmaceutics at the Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan. His research expertise is in transporter-based drug delivery/targeting the eye and brain. He has published 94 peer-reviewed articles and written 33 book chapters/reviews.

**Bhaskara R. Jasti, Ph.D.** is Professor and Chairman of the Department of Pharmaceutics and Medicinal Chemistry, at University of the Pacific. His lab is studying the influence of ionic species, predictive models in oral mucosal drug delivery, and he is designing micelles with cell adhesion receptors (integrin ligands) for the targeted delivery of chemotherapeutic agents. He is a founding member and has served as Chair of the AAPS Bay Area Discussion Group, and has published over 80 peer-reviewed articles, book chapters, and co-edited two books.

**Rajesh Krishna, Ph.D., FCP** is Head of Quantitative Clinical Pharmacology at Merck. He is a leader in quantitative clinical pharmacology, specifically as it relates to model-based prediction of benefit and risk using decision analysis, dose optimization, and innovation in clinical trial designs. He has authored more than 115 original research articles, invited reviews, book chapters, and oral/poster presentations, and edited three books, in addition to serving as a reviewer for numerous journals in the field.

**Tamara Minko, Ph.D.** is Professor and Chair of the Department of Pharmaceutics at Rutgers, The State University of New Jersey. Her current research interests include drug delivery, biopharmaceutics, nanotechnology for cancer detection and treatment, molecular targeting, mechanisms of multidrug resistance, and bioimaging use of macromolecules for drug delivery.

**Russell J. Mumper, Ph.D.** is Distinguished Professor and Director of the Center for Nanotechnology in Drug Delivery at the University of North Carolina, Eshelman School of Pharmacy. He has made contributions to the creation of drug, gene, and vaccine delivery systems leading to several first-in-human studies over the past 20 years. His current research focuses on nanoparticle-based systems to overcome resistance in cancer, and their use as vaccine delivery systems to co-deliver protein antigens and adjuvants. Over the past 10 years, he has led seven university-based product development efforts resulting in first-in-human clinical trials.

**Eric J. Munson, Ph.D.** is Professor of Pharmaceutical Chemistry at the University of Kansas. His research program is focused on the characterization of pharmaceutical solids using a variety of analytical techniques, with an emphasis on solid-state Nuclear Magnetic Resonance spectroscopy. He is a recipient of a National Science Foundation CAREER award and a McKnight Land-Grant Professorship.

**Yihong Qiu, Ph.D.** is a Volwiler Research Fellow at Abbott Laboratories. His contributions to the fields of modified-release drug delivery, science-based product development, improvement of dissolution, bioavailability, and in vitro-in vivo correlation (IVIVC) are reflected by the publication of 43 original papers and books, 30 patents, as well as 42 oral and 26 poster presentations that have been widely cited. He is a recognized expert of oral product design and development who has successfully brought delivery technology and blockbuster drug products from research and development to commercialization and made pioneering achievements in drug release and IVIVC since the early 1990's.

**Indra K. Reddy, Ph.D.** is Professor and Founding Dean of the Texas A&M Health Science Center, Irma Lerma Rangel College of Pharmacy. He has been recognized for his innovative contributions in the areas of design of novel ocular drugs and delivery systems, preformulation and evaluation of targeted and site-specific chemical delivery systems, and the development of in vitro models as alternatives to animal testing. He has authored/co-authored six textbooks; written 13 book chapters; edited two reference books; and published over 100 research and review articles.

**Robert A. Reed, Ph.D.** is currently Executive Director, Chemistry Manufacturing and Controls and Technical Operations at Celsion Corp. in Columbia, Md. He has been a major contributor to the successful commercialization of 25 products. His

research interests include understanding unexpected pharmaceutical product photochemistry through identification of critical quality relationships, serving to guide effective control strategies, and the role of excipients in chemical and photochemical stability of pharmaceutical products.

**A. David Rodrigues, Ph.D.** is an executive with Bristol-Myers Squibb in Princeton, N.J. During the last 20 years, he has devoted a major part of his career to the study of how drugs interact with biologic systems. In particular, he has focused on the development of tools, models, and techniques to predict drug-drug and drug-protein interactions in humans, so that drug combinations are safer and more effective. He has published approximately 100 manuscripts, sits on the editorial review boards of three scientific journals, has edited a successful book, and has presented at numerous national and international conferences.

**Clinton Fields Stewart, Pharm.D.** is a Full Member in the Department of Pharmaceutical Sciences at St. Jude Children's Research Hospital and Professor of Pediatrics and Clinical Pharmacy at the University of Tennessee at Memphis. His research efforts are focused on addressing clinically relevant problems of cancer therapeutics in children. As Co-chair of the Pharmacology Committee of the Pediatric Brain Tumor Consortium, Dr. Stewart has an active research program focused on developing a better understanding of the Central Nervous System penetration of anti-cancer drugs. He has authored or co-authored more than 190 peer-reviewed articles and book chapters.

**Hiroshi Suzuki, Ph.D.** is Professor and Chairman of the Department of Pharmacy at The University of Tokyo Hospital. He has been working to clarify the role of drug transporters in drug disposition. Recently, he has started working on clinical systems-biology, in order to establish methods to predict the pharmacodynamic / toxicodynamic effects from in vitro data and/or biomarkers. His method is already used in clinical situations and will have an impact from the regulatory aspects of human clinical trials during the drug development.

**Peter W. Swaan, Ph.D.** is Professor of Pharmaceutical Sciences and Director of the Center for Nanomedicine and Cellular Delivery at the University of Maryland, School of Pharmacy in Baltimore. He has published over 80 original research articles focusing on all aspects of transport proteins in drug targeting and delivery, pharmacokinetics and pharmacodynamics. His major contributions to this research area involve the application of transporters as targets for prodrugs. He holds several U.S. patents and serves as Editor-in-Chief for *Pharmaceutical Research*.

**Yoshinobu Takakura, Ph.D.** is Professor at the University of Kyoto (Japan). He has conducted a series of studies in macromolecular drug delivery in the field of biopharmaceutics. Recent research interests include nucleic acid drug delivery for the optimization of gene therapy, DNA vaccination and RNAi-based therapies. Dr. Takakura has published 228 peer reviewed original research articles, 30 review articles, and 18 book chapters.

**Cheryl L. Zimmerman, Ph.D.** is Professor and Director of Graduate Studies in Pharmaceutics at the University of Minnesota. Her research efforts center on a detailed delineation of the absorption and disposition of drugs and prodrugs with a particular emphasis on intestinal metabolism and activation, as well as the pulmonary metabolism of the carcinogens tobacco-specific nitrosamines and their role in transforming healthy cells into cancer cells (carcinogenesis). She has trained 10 Ph.D. and five M.S. students over her 25 years in academia, is a past Chair of the Pharmacokinetics, Pharmacodynamics and Drug Metabolism section of AAPS, and served as a Member-at-Large on the AAPS Executive Council from 2004-2006.

\* \* \*

## About AAPS

The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific society of approximately 12,000 members employed in academia, industry, government and other research institutes worldwide. Founded in 1986, AAPS provides a dynamic international forum for the exchange of knowledge among scientists to enhance their contributions to health. AAPS offers timely scientific programs, on-going education, information resources, and opportunities for networking and professional development. To learn more about AAPS, please visit [www.aapspharmaceutica.com](http://www.aapspharmaceutica.com).

**Editors Note:** To request an interview with or photograph of a 2009 Award Winner, please contact Joe Catapano at [CatapanoJ@aaps.org](mailto:CatapanoJ@aaps.org), or on-site at the 2009 AAPS Annual Meeting and Exposition Press Room, located in Room 511AB of the Los Angeles Convention Center, at 213-743-6208. Copies of the 2009 AAPS Awards Program are also available for media use.

American Association of Pharmaceutical Scientists  
2107 Wilson Blvd, Suite 700, Arlington, VA 22201-3042  
Main Telephone: 703 243 2800 Main Fax: 703 243 9650  
Email: [AAPS](mailto:AAPS)

[View disclaimer](#)

[View Privacy Statement](#)

Please email your comments or questions regarding this web site to  
[Webmaster](#)